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Edited by Lukas HuberAbstract We show that phorbol ester treatment of NIH 3T3
ﬁbroblasts induces rapid translocation of PKCe from a perinu-
clear site to the nucleus, extending ﬁndings in PC12 and NG108-
15 cells and in myocytes. We have immunoprecipitated the PKCe
from nuclei isolated from phorbol ester-treated ﬁbroblasts and
identiﬁed six proteins which associate with nuclear PKCe. These
have been characterised as matrin 3, transferrin, Rac GTPase
activating protein 1, vimentin, b-actin and annexin II by
MALDI–TOF–MS. We have conﬁrmed that these proteins
associate with PKCe by gel overlay and/or dot blotting assays.
The role of these PKCe-associating proteins in the nucleus and
their interaction with PKCe are considered.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Translocation of protein kinase C isoforms from the cytosol
to the plasma membrane is a commonly observed eﬀect fol-
lowing the stimulation of cells with a range of ligands in-
cluding phorbol ester analogues of diacylglycerol (DAG) [1,2].
This translocation results in activation and turnover of the
kinase and the phosphorylation of downstream substrates [3].
Translocation of PKC isoforms to cell compartments other
than the plasma membrane has also been reported [4,5]. PKCe,
for example, translocates from a perinuclear region to the
cytosol on ethanol treatment of NG108-15 cells [6] while the
anticancer agent cis-diamminedichloroplatinum induces
translocation from the plasma membrane to the cytosol and
nuclear membrane in SKBR-3 cells [7]. PKCe is the only fully
oncogenic PKC isoform and its translocation to the nucleus
occurs, for example, when NG108-15 cells are stimulated with
phorbol ester, when myocytes are treated with arachidonic* Corresponding author. Fax: +44-1904-328505.
E-mail address: mgr1@york.ac.uk (M.G. Rumsby).
Abbreviations: DAG, diacylglycerol; DIC, diﬀerential interference
contrast; GFP, green ﬂuorescent protein; MALDI–TOF–MS, ma-
trix-assisted laser desorption/ionisation time of ﬂight mass spectrom-
etry; NGS, normal goat serum; NLS, nuclear localisation sequence;
PKC, protein kinase C; PMA, phorbol 12-myristate 13-acetate; Rac
GAP1, Rac GTPase-activating protein 1; RACK, receptor for
activated C kinase
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doi:10.1016/j.febslet.2004.05.080acid, when PC12 cells are treated with serum [6,8,9] or in is-
chaemic preconditioning [10]. Indeed, a role for PKCe trans-
location to the nucleus in cardioprotection has been suggested
[11] but target substrates that PKCe associates with in the
nucleus are not well deﬁned. Here we show that phorbol ester
treatment of 3T3 ﬁbroblasts induces PKCe translocation to the
nucleus. We have recovered six proteins which associate with
nuclear PKCe and have identiﬁed them by MALDI-TOF mass
spectrometry as being involved in regulating cell proliferation,
apoptosis, DNA replication, mRNA processing and nucleo-
skeleton organisation.2. Materials and methods
2.1. Cell culture and immunoﬂuorescence
NIH3T3 cells (ECACC, Porton Down, UK) were grown in Dul-
becco’s modiﬁed Eagle’s medium (DMEM) supplemented with 10%
fetal calf serum and antibiotics (Gibco BRL, Paisley, UK) to about
80% conﬂuency. For experiments, cells were passaged in fresh medium
into 4-chamber culture slides or plastic dishes 24 h before treatments.
Cells in 4-chamber culture slides (Nunc, Life Technologies, Paisley,
UK) were treated with 1 lM PMA or DMSO vehicle for 30 min and
PKCe was detected by immunoﬂuorescence as described previously
[12].
2.2. Construction of a plasmid encoding GFP-PKCe fusion protein and
observation in living cells
A plasmid containing humanised GFP cDNA (pEGFP-C1) was
obtained from Clontech (Palo Alto, USA). The PKCe encoding
sequence was generated by PCR from a pGEM-PKCe plasmid [13].
The sense primer with a Bg1 II restriction site was 50-GAGA-
AGATCTATGGTAGTGTTCAATGGCCTTC-30. The antisense
primer with an EcoRI site was 50-TCTCGAATTCTCAGGGCAT-
CAGGTCTTCACC-30. The insert was conﬁrmed by sequencing. 3T3
cells were transfected with the GFP-PKCe plasmid using Polyfect
Transfection Reagent (Qiagen) using the maker’s protocol. Cells were
treated with 1 lM PMA or DMSO 24 h after transfection. Translo-
cation of GFP-PKCe was monitored under a Zeiss confocal laser
scanning microscope at 37 C in a hood supplied with 5% CO2.2.3. Isolation of nuclei
Nuclei were isolated as described by Dignam et al. [14] with modi-
ﬁcations. Cells treated with PMA (30 min) or vehicle were scraped
from dishes in cold PBS and pelleted by centrifugation at 700 g for 5
min. Pelleted cells were resuspended in 5 vols hypotonic buﬀer (15 mM
Tris–HCl, 15 mM NaCl, 60 mM KCl, 0.5 mM EDTA, pH 7.4, plus
protease inhibitor cocktail) and left on ice for 15 min. Cells were then
lysed with 0.5% Triton X-100 (ﬁnal concentration) and passed several
times through a 23-gauge needle. Nuclei were then pelleted at 1000 g
for 10 min. The pelleted nuclei were washed twice by resuspension in
cold PBS and centrifuged at 25 000 g for 20 min to remove residual
cytoplasmic material. The purity of the nuclear fraction was examined
by staining with 1 lg/ml DAPI for 15 min at 37 C and observationblished by Elsevier B.V. All rights reserved.
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preparation for cytoplasmic contamination, aliquots of the superna-
tant above the nuclear pellets and of nuclear lysate were resolved by
SDS–PAGE, followed by Western blotting with a monoclonal anti-
body (1:10 000) to detect a-tubulin.
2.4. Co-immunoprecipitation of proteins binding to nuclear PKCe and
MALDI–TOF–MS analysis
Nuclei from PMA-treated cells were resuspended in immunopre-
cipitation buﬀer (50 mM Tris–HCl, 300 mMNaCl, 5 mM EDTA, 0.5%
SDS, 1% Triton X-100, 1 mM PMSF, 2 lg/ml leupeptin, 1 mM AE-
BSF, pH 7.4) and passed several times through a 25-gauge needle. The
nuclear lysate was centrifuged at 14 000 g for 10 min to remove any
insoluble proteins, analysed for protein content (BCA assay) and then
precleared with protein G-sepharose (PGS) for 1 h. The precleared
nuclear lysate was divided into two samples, each containing equal
amounts of nuclear protein. One sample was then incubated with
mouse anti-PKCe antibody (17 lg/ml in ﬁnal concentration) and the
other with mouse IgG for 2 h. Antibody complexes were recovered
with PGS beads. After rinsing the beads three times with immuno-
precipitation buﬀer, proteins were solubilised in Laemmli or thiourea
buﬀer. Immunoprecipitates were resolved by SDS–PAGE (8–18% gels)
or 2D electrophoresis and proteins located by silver staining. Speciﬁc
bands or dots were excised into 1 mm blocks. After destaining, the
blocks were dehydrated with acetonitrile. Samples were digested with
trypsin (Promega, Madison, USA) overnight at 37 C. A 1 ll aliquot of
digestion supernatant was spotted onto a MALDI–TOF–MS sample
plate with 0.6 ll matrix and allowed to air-dry. An Applied Biosystems
4700 Proteomics Analyser, coupled with tandem mass spectrometry
(MS/MS), was used to generate peptide mass ﬁngerprints. These were
searched against the NCBInr public database. A mass ﬁngerprint was
considered a signiﬁcant match if the score was equal to or greater than
75.
2.5. Gel overlay assay for PKCe-binding proteins in nuclei
Nuclear proteins were resolved by SDS–PAGE and transferred to
nitrocellulose membranes. After blocking, the membranes were incu-
bated with 2 lg/ml recombinant PKCe (CalBiochem, Nottingham,
UK) in 1% milk powder (Marvel) in TBS for 2 h followed by three
rinses with TBS. Membranes were then processed for Western blotting
with a PKCe antibody (1:200) as above. Controls were incubated with
1% milk powder lacking PKCe.
2.6. Dot blot assay
For dot blotting, puriﬁed transferrin, vimentin, b-actin and annexin
II (Sigma) were applied directly to nitrocellulose membrane: as a
control, an equal amount of BSA was applied. Protein spots were air
dried and membranes were then blocked with 5% milk powder in TBS.Fig. 1. PMA induces the nuclear translocation of PKCe in ﬁbroblasts. (A)
predominantly localised in the perinuclear region of cells treated with DMSO
translocated to nucleus. (B) Real time observation of GFP-PKCe in living 3T3
localised in a perinuclear region; 5 m, after 5 min GFP-PKCe is still localised
the nucleus; 30 m, after 30 min most GFP-PKCe has moved to nucleus. (C) W
nuclei from DMSO vehicle treated cells is low. PMA, PKCe in nuclei from PThe membranes were then incubated with 2 lg/ml recombinant PKCe
in 1% milk powder in TBS overnight and rinsed three times with TBS.
After washes, the membranes were processed for Western blotting with
a PKCe antibody (1:200) as above.3. Results
3.1. PKCe translocates to the nucleus upon PMA stimulation in
ﬁbroblasts
In normal ﬁbroblasts PKCe has a mainly perinuclear lo-
calisation (Fig. 1A, CON). Treatment of cells with 1 lM PMA
for 30 min induced an obvious translocation to the nucleus as
revealed by the increased ﬂuorescence associated with the
nucleus and the decrease in PKCe localisation in the perinu-
clear region (Fig. 1A, PMA). To conﬁrm this, we transfected
NIH3T3 with GFP-PKCe and monitored the real time trans-
location of GFP-PKCe in living cells treated with 1 lM PMA
by confocal microscopy for up to 60 min. In agreement with
the immunoﬂuorescence results, GFP-PKCe was localised in
the perinuclear region before PMA stimulation (Fig. 1B, 0 m)
but translocated to the nucleus on PMA stimulation. This real
time translocation to the nucleus was especially obvious after
30 min (Fig. 1B, 30 m). To conﬁrm this ﬁnding further, we
isolated nuclei from control and PMA-treated ﬁbroblasts and
analysed them for PKCe by Western blotting. As shown in
Fig. 1C, the PKCe band was more intense in nuclei of cells
treated with PMA conﬁrming that phorbol ester treatment of
ﬁbroblasts induces the nuclear translocation of PKCe.
3.2. Identiﬁcation of nuclear PKCe-binding proteins in
PMA-treated ﬁbroblasts
We isolated nuclei from PMA-treated cells and coimmuno-
precipitated PKCe-associating proteins for identiﬁcation by
MALDI–TOF–MS. The accuracy of such experiments de-
pends on the purity of the nuclei so this was examined by
DAPI staining and by Western blotting. Staining the nuclei
preparation with DAPI matched the diﬀerential interference
contrast (DIC) picture of a typical nuclei preparation with no
obvious contamination by other organelles such as endoplas-Immunoﬂuorescence staining of PKCe in 3T3 cells. CON, PKCe is
vehicle. PMA, PKCe in cells treated with 1 lM PMA for 30 min has
cells treated with 1 lM PMA. 0 m, on addition of PMA GFP-PKCe is
in perinuclear region; 15 m, after 15 min some GFP-PKCe moves into
estern blotting detection of PKCe in nuclei. CON, The level of PKCe in
MA treated cells is increased. Scale bar in (A) and (B) represents 5 lm.
Fig. 2. Purity of nuclear preparations. (A) Puriﬁed nuclei were stained
with the DNA binding dye DAPI and compared with the DIC image.
The merged DAPI/DIC image suggests nuclei were highly puriﬁed with
no evidence of contaminating organelles. (B) The cytoskeleton protein
a-tubulin was not detected in the lysate of puriﬁed nuclei, but was
present in the cytoplasmic fraction. Scale bar in (A) represents 5 lm.
Fig. 3. Identiﬁcation of PKCe coimmunoprecipitates on gradient gels.
Proteins coimmunoprecipitating with nuclear PKCe were separated on
8–18% gradient gels and stained by MALDI–TOF–MS-compatible
silver staining. Lane M, markers; Lane IgG, mouse IgG coimmuno-
precipitate control; Lane PKCe, PKCe coimmunoprecipitate. By this
approach 5 proteins, matrin 3 (125 kDa), transferrin (80 kDa),
Rac GAP1 (70 kDa), vimentin (50 kDa) and b-actin (42 kDa) were
identiﬁed.
Fig. 4. Gel overlay and dot blotting. (A) Gel overlay assay. Results
conﬁrm that the six proteins identiﬁed in the nuclear PKCe immuno-
precipitates bind recombinant PKCe compared with controls (Con).
(B) Dot blotting assay. Results in duplicate conﬁrm that transferrin,
vimentin, b-actin and annexin II bind PKCe whereas BSA control does
not.
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blotting for a typical cytoplasmic/cytoskeletal protein, a-tu-
bulin, which was not detected in the nuclear preparation
(Fig. 2B).
To minimise the possibility of artiﬁcial binding of proteins to
PGS beads, we precleared the nuclear lysate and used a mouse
IgG control. Immunoprecipitates were separated on 8–18%
gradient gels and only bands absent from or increased in
concentration over IgG control immunoprecipitates were ta-
ken for MALDI–TOF–MS identiﬁcation. We found that ﬁve
proteins met such criteria (Fig. 3). With more precise 2D
electrophoresis, another protein, annexin II, was also identiﬁed
in PKCe immunoprecipitates (data not shown). The protein
score in MALDI–TOF–MS, accession number in NCBInr and
role in the nucleus for these six proteins are summarised in
Table 1. Another three proteins were detected in PKCe im-
munoprecipitates compared with IgG control, but as we have
not yet conﬁrmed that these bind PKCe by gel overlay or dot
blotting they are not included in Table 1.
3.3. Conﬁrmation of PKCe-binding by gel overlay and dot
blotting assays
We conﬁrmed that the six proteins identiﬁed in PKCe co-
immunoprecipitates associated with recombinant PKCe by gel
overlay assays. As shown in Fig. 4A proteins associating with
PKCe were detected at the expected molecular sizes for the six
proteins identiﬁed by MALDI–TOF–MS (Table 1) compared
with control blots not incubated with recombinant PKCe.
Four of the nuclear proteins identiﬁed binding to PKCe,
transferrin, vimentin, b-actin and annexin II are available
commercially, so we veriﬁed that these proteins associated with
PKCe by a dot blotting assay showing duplicate resultsTable 1
MALDI–TOF–MS identiﬁcation of proteins associating with nuclear PKCe in 3T3 cells
Protein MW (kDa) Accession number Protein score in MALDI–TOF–MS Main role in nucleus
Matrin 3 93a gij25141233 458 RNA splicing
Transferrin 80 gij21363012 112 Cell proliferation
Rac GAP1 70 gij6755266 195 Cytokinesis
Vimentin 51 gij2078001 186 Chromatin organisation
Actin beta 42 gij71619 94 mRNA transcription
Annexin II 37 gij71763 90 DNA replication
aApparent molecular weight on SDS–PAGE is 125 kDa [24].
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bind PKCe (Fig. 4B).4. Discussion
Translocation of PKC isoforms on cell stimulation occurs to
activate the kinase, to bring the activated enzyme into asso-
ciation with downstream substrates and to initiate its inacti-
vation [3]. PKC isoforms require a phosphatidylserine surface
in membranes for activity but, for full activation, novel PKCe
requires DAG generated in membranes by hydrolysis of
phosphatidylinositol 4,5-bisphosphate (PIP2) by a phosphati-
dylinositol-phospholipase C. Cell stimulation can induce
PKCe translocation to the plasma membrane [1], the Golgi
apparatus [15], a perinuclear localisation [16], mitochondria
[17] or the nuclear membrane and into the nucleus [4,6]. Nu-
clear translocation has been noted in PC12, NG108-15 cells
and myocytes treated with serum, phorbol ester and arachi-
donic acid respectively and is also induced by ischaemic
preconditioning which leads to cardioprotection [10]. Trans-
location of PKCe to the nucleus is of interest since this isoform
has oncogenic potential and is implicated in cardioprotection
[11]. It thus becomes important to identify the proteins inter-
acting with PKCe after entry into the nucleus. We show here
by three methods, including examination in living cells, that
phorbol ester stimulation of ﬁbroblasts induces PKCe trans-
location to the nucleus. This ﬁnding therefore extends the
range of cells in which nuclear translocation of PKCe has been
observed. Some PKCe is present in the nuclei of ﬁbroblasts
prior to PMA treatment as revealed by our immunoﬂuores-
cence and Western blotting results but levels of nuclear PKCe
clearly increase on PMA treatment. Nuclear PKCe may be in
an activated state since DAG occurs within the nucleus [18,19].
Levels of nuclear DAG can alter during the cell cycle and
generation of polyunsaturated DAG species correlates with
PKC activation [20]. Tetra unsaturated species of DAG in-
crease during the G2/M phase of the cell cycle and lead to
translocation of PKCbII to the nucleus at G2/M [19]. How
PMA added exogenously to ﬁbroblasts causes PKCe move-
ment to the nucleus is not clear though nuclei have receptors
for PMA [21] while a cytosolic PMA-binding protein can
function in HeLa cells to transport PMA to the nucleus [22].
The latest prediction software indicates that PKCe lacks a
nuclear localisation sequence (NLS) in agreement with
Wooeten et al. [23]. However, PKCe activated at the plasma
membrane by PMA may be co-transported to the nucleus in
association with a protein which has an NLS. Interestingly,
matrin 3 which we have identiﬁed as a binding partner for
PKCe in the nucleus, has a potential NLS [24]. Matrin 3, a
component of the ﬁbrogranular nucleoskeleton with eleven
potential PKC phosphorylation sites (as identiﬁed using
Phosphobase [25]) may therefore be a substrate of PKCe. We
are now investigating whether phosphorylation of matrin 3 by
PKCe enhances movement of a kinase-matrin 3 complex to the
nucleus where transcription and RNA splicing, known func-
tions of matrin 3 [24,26,27], would be inﬂuenced.
Four of the ﬁve other proteins we have identiﬁed associating
with PKCe in the nucleus, namely vimentin, transferrin, ann-
exin II and RacGAP1 are regulated by phosphorylation which
may explain their association with PKCe. Vimentin, involvedin chromatin organisation and nuclear matrix core ﬁlament
construction [28], has eleven PKC phosphorylation sites [25]
while iron-binding transferrin, which can bind to DNA with
strong aﬃnity, has seven [25]. RacGAP1 mainly localises in the
nucleus in interphase, accumulates on the mitotic spindle in
metaphase and condenses in the midbody [29]. Phosphoryla-
tion at Ser387 is important for the cytokinesis function of
RacGAP1. Aurora B might be responsible for this phosphor-
ylation [30] but our results suggest that PKCe in the nucleus
might also inﬂuence the function of RacGAP1. Nuclear ann-
exin II, implicated in DNA replication and cell proliferation
[31,32], is also regulated by phosphorylation at Ser11 and
Ser25 in the nuclear export signal domain [32].
Actin is a normal component of the nucleus involved in
mRNA transcription and nuclear assembly [33,34]. It is not
surprising that we detected actin associated with nuclear PKCe
since this isoform has a unique actin binding motif and the
association of actin with PKCe can maintain the kinase in a
catalytically-active conformation [35].
A role for PKCe translocation to the nucleus in protection
against ischaemic injury [11] has been identiﬁed, making it
essential to identify the precise pathways by which this event
protects against myocardial ischaemia. This will be achieved
when the proteins that PKCe associates with in the nucleus are
deﬁned, determining which are substrates and which are re-
ceptors for activated C-kinase (RACKS) localising PKCe to
speciﬁc nuclear sites.
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